New tests are now available to help researchers unravel the complexities of cerebrovascular disease and other neurological disorders
Revolutionary biochip array technology developed by Randox Laboratories enables simultaneous testing of up to 23 biomarkers for each patient sample.
Cerebrovascular disease is one of the main causes of overall mortality.
67,000 deaths due to stroke occur in the UK each year.
This figure is just above that for dementia, which claims 60,000 UK deaths each year.
Research into the causes of these and other neurological disorders will give insight into the disease process and may help find preventive measures against the diseases.
As Randox recognises the importance of information, biomarkers such as FABP, GFAP, D-Dimer, NGAL and NSE among others have been arranged as biochip arrays to help gain more knowledge about cerebrovascular disease, Alzheimer's dementia and multiple sclerosis.
Biochip array technology enables the simultaneous measurement of different analytes with a single sample and a single analytical device, thus reducing biological variation and enabling patient profiling from one small sample.
Randox is an international diagnostics company, headquartered in the UK.
Randox develops, manufactures, and markets clinical diagnostic products worldwide.
Core products are biochip array technology; clinical chemistry analysers and reagents; quality controls and EQA; environmental diagnostics; recombinant proteins and antibodies.
